Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Combo Pharma's gross profit for the
six
months ended in Jun. 2026 was A$2.46 Mil. Star Combo Pharma's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was A$6.47 Mil.
Star Combo Pharma (ASX:S66) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Star Combo Pharma had a gross margin of 21.16% for the quarter that ended in Jun. 2026 => Competition eroding margins
Star Combo Pharma Gross Profit Related Terms
Star Combo Pharma Gross Profit Historical Data
* Premium members only.
The historical data trend for Star Combo Pharma's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Star Combo Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Combo Pharma Gross Profit vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's Gross Profit distribution charts can be found below:
* The bar in red indicates where Star Combo Pharma's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$6.47 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Star Combo Pharma (ASX:S66) has a Gross Profit of A$6.47 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Star Combo Pharma and its competitors.
Is Star Combo Pharma's Gross Profit too high?
Star Combo Pharma's current Gross Profit is A$6.47 Mil. Overall, Star Combo Pharma has a GF Score™ of 20/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's Gross Profit compare to PG and CL?
Star Combo Pharma's Gross Profit of A$6.47 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Consumer Packaged Goods company?
A good Gross Profit depends on the Consumer Packaged Goods industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Star Combo Pharma and its competitors. Star Combo Pharma's current Gross Profit is A$6.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.14 — trading 7.7% above its estimated fair value. The current Gross Profit is A$6.47 Mil. Star Combo Pharma's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current Gross Profit is A$6.47 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Combo Pharma (ASX:S66) Overvalued in 2026?
Based on GuruFocus' analysis, Star Combo Pharma stock appears to be overvalued.
The current stock price of A$0.14 is trading 7.7% above its estimated GF Value™ of A$0.13.
GuruFocus considers Star Combo Pharma to be Fairly Valued.
Key valuation signals for ASX:S66:
Gross Profit: A$6.47 Mil
GF Value™: A$0.13 vs. price of A$0.14 (7.7% above fair value)
No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
20GF Score
Get the complete analysis for ASX:S66
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:S66 has been successfully added to your 
